Latest Market News
Shares of Affirm Holdings Inc. AFRM, -6.17% were up more than 3% in premarket trading Thursday after the company announced that it would launch a buy-now-pay-later option on Amazon.com Inc.’s AMZN, -1.54% site in Canada. The company already has a relationship with Amazon in the U.S. Affirm noted in a Thursday press release that eligible […]
Greenback continues to gain more ground thanks to a “welcomed” mix of geopolitical instability and increasing policy lag between the Fed and other major central banks. Even though the market positioned itself for a “worst-case” meeting scenario, the Fed managed to surprise even hawks with its updated dot plot projections. They indicated sharp revisions in […]
Type: Bullish Rise Key Levels:Resistance: 147.900Pivot: 144.275Support: 141.100 Preferred Case:On the H4, with price moving along the ascending trendline and above the ichimoku indicator, we have a bullish bias that price will rise from the pivot at 144.275 to the 1st resistance at 147.900 where the 127.2% fibonacci extension is. Alternative Scenario:Alternatively, price could break […]
The Central Bank of Bahrain gives the nod to EazyPay, launching crypto payments for more than 5,000 payment gateways in the country. 1364 Total views 24 Total shares Cryptocurrency adoption continues growing in the Kingdom of Bahrain, with local companies enabling payments in crypto like Bitcoin (BTC). EazyPay, an online payment platform regulated by the […]
Shares of Graphic Packaging Holding Co. GPK, +0.74% hiked up 0.9%, to buck the selloff in the broader stock market, after the consumer packaging provider said it raised its quarterly dividend by 33%. The new dividend of 10.0 cents a share, up from 7.5 cents a share, will be payable Jan. 5, 2023 to shareholders […]
Shares of Spero Therapeutics Inc. SPRO, +226.76% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.34% for its experimental antibiotic for complicated urinary tract infections. Spero’s therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year. If approved, it would offer patients […]